Guido Kroemer, Ph.D.
Professor at the Faculty of Medicine of the University of Paris Descartes, Director of the research team "Apoptosis, Cancer and Immunity" of the French Medical Research Council (INSERM), Director of the Metabolomics and Cell Biology platforms of the Gustave Roussy Comprehensive Cancer Center, Deputy Director of the Cordeliers Research Center, and Hospital Practitioner at the Hôpital Européen George Pompidou, Paris, France. He is also a Foreign Adjunct Professor at the Karolinska Institute, Stockholm, Sweden.
Kroemer completed medical school at the University of Innsbruck in Austria and earned a Ph.D. in biology from the Autonomous University of Madrid. Early in his career, Kroemer worked for the Spanish National Research Council. Now based in France, he is a cell biology researcher with INSERM and a Professor of the Faculty of Medicine of Paris Descartes University. Kroemer first discovered the fact that mitochondrial membrane permeabilization is a concrete step in the process of programmed cell death.
In a publication analysis by the news magazine Lab Times, Kroemer was the most highly cited cell biologist for the period between 2007 and 2013. Three other scientists who had worked at Kroemer's lab were also highly ranked in the analysis. In 2007, Kroemer was elected a member of the Academy of Sciences Leopoldina, the national academy of Germany. The same year, he received the organization's Carus Medal. He was named a fellow of the European Academy of Sciences in 2010. In 2012, he won the Leopold Griffuel Prize from the French ARC Foundation for Cancer Research. Kroemer is the editor-in-chief of the journal Cell Death & Disease.
Steven Artandi. M.D., Professor
Stanford University, California, USA
Dr. Steven Artandi is a hematologist in Stanford, California and is affiliated with multiple hospitals in the area, including Stanford Health Care-Stanford Hospital and VA Palo Alto Health Care System. He received his medical degree from Columbia University College of Physicians & Surgeons and has been in practice for more than 20 years. Dr. Artandi accepts several types of health insurance, listed below. He is one of 50 doctors at Stanford Health Care-Stanford Hospital and one of 21 at VA Palo Alto Health Care System who specialize in Hematology.
Meharvan Singh, PhD
Director, Center for Alzheimer’s and Neurodegenerative Disease Research
Interim Director, Institute for Healthy Aging
Professor, Department of Pharmacology and Neuroscience,
University of North Texas Health Science Center
Dr. Meharvan “Sonny” Singh left Columbia University Medical Center in New York to join UNT Health Science Center in 2001, and is currently Professor and Interim Director for the Institute for Healthy Aging, a multi-disciplinary research- and education-focused institute that is home to faculty at UNT Health Science Center conducting basic biomedical research, translational research, and clinical studies into the early diagnosis, prevention, and treatment of age-related conditions that include such neurodegenerative diseases as Alzheimer’s disease.
Dr. Singh has spent his career focusing on how hormones, like estrogen, progesterone and testosterone, affect the brain, particularly within the context of “normal” brain aging and such degenerative diseases as Alzheimer’s disease. As such, his research addresses the potential role of these hormones and their associated signaling pathways in the observed sex differences in the prevalence and/or risk for age-associated diseases. His research has led to numerous publications that have helped shape our current understanding of how hormones affect the brain.
His commitment to research and the education of the next generation of research scientists has been recognized through several awards, including the Outstanding Faculty Member Award in 2006, the President’s Research Educator Award in 2012, the Health Care Hero Award from the Fort Worth Business Press in 2013, and the Edward E. Elko Award for Distinguished Service to the Graduate Student Association in 2017, in addition to serving as Principal Director/PI of an NIH-funded training grant (T32) in the Neurobiology of Aging.
Ilia Stambler, PhD
Outreach Coordinator. International Society on Aging and Disease - ISOAD http://isoad.org <http://isoad.org/>
Chair. Israeli Longevity Alliance / CSO. Vetek (Seniority) Association – The Senior Citizens Movement (Israel) http://www.longevityisrael.org/
Coordinator. Longevity for All http://www.longevityforall.org <http://www.longevityforall.org/>
Author. Longevity History. A History of Life-Extensionism in the Twentieth Century ; Longevity Promotion: Multidisciplinary Perspectives http://longevityhistory.com <http://longevityhistory.com/>
Email: firstname.lastname@example.org <mailto:email@example.com>
Prof. Ewa Sikora, PhD
Laboratory of Molecular Bases of Aging,
Nencki Institute of Experimental Biology,
Polish Academy of Sciences,
02-093 Warsaw, Poland
Francesca Cirulli, Ph.D.
Center for Behavioral Sciences and Mental Health
Istituto Superiore di Sanità
Viale Regina Elena 299, 00161 Rome, Italy
President European Brain and Behaviour Society
Anton Kulaga <firstname.lastname@example.org>
Bioinformatician at Computational Biology of Aging Group
296 Splaiul Independentei, Bucharest, Romania, 060031
Pr Nicolas LEVY
Nicolas LEVY <email@example.com>
Nice, IPMC, France
Thierry Galli <firstname.lastname@example.org>
Per Pierre Soubeyran
Soubeyran Pierre <P.Soubeyran@bordeaux.unicancer.fr>
Valery Krizhanovsky, PhD
Department of Molecular Cell Biology
Weizmann Institute of Science
Web: http://www.weizmann.ac.il/mcb/valery/ <http://www.weizmann.ac.il/mcb/valery/>
George A. Garinis
Professor, University of Crete
Group leader, IMBB-FORTH
"George A. Garinis" <email@example.com>
Institute of Molecular Biology and Biotechnology
Foundation for Research and Technology - Hellas
Nikolaou Plastira 100
GR-70013, Heraklion, Crete
Pr Jackie Han
Miguel Godinho Ferreira PhD DR2
Miguel Godinho Ferreira <Miguel-Godinho.Ferreira@unice.fr>
Telomere shortening team
IRCAN - Institute for Research on Cancer and Aging
Pr Olivier GUERIN
Olivier Guérin, MD, PhD
GUERIN OLIVIER CHU Nice <firstname.lastname@example.org>
Professeur des Universités-Praticien Hospitalier
IRCAN - Université de Nice - Sophia-Antipolis INSERM U1081 - CNRS UMR 7284
Chef du Pôle Réhabilitation Autonomie Vieillissement (RAV)
CHU de Nice, Hôpital de Cimiez, 4 ave Reine Victoria 06000 Nice
Dr. Oliver BISCHOF | Institut Pasteur
Unité "Organisation Nucléaire et Oncogenèse" - Inserm U993
Bâtiment André Lwoff
28, rue du Dr. Roux
75724 Paris Cedex 15 - France
Pr Dr Patrizia D'ALESSIO MD PhD
Patrizia D'Alessio <email@example.com>
AISA Therapeutics Award Innovative Entrepreneurship Ministry of Research France www.aisa-tx.com <http://www.aisa-tx.com/>
University Paris Sud-11 and Biopark Cancer Campus 1 mail Pr Georges Mathé 94807 Villejuif France
firstname.lastname@example.org email@example.com Cell +33-6-87478032 www.aisa-care.com <http://www.aisa-care.com/>
Pr Paul Hofman
HOFMAN PAUL CHU Nice <HOFMAN.P@chu-nice.fr>
Pr. Patrick BAQUE
Doyen de la Faculté de Médecine de Nice
28, avenue de Valombrose
06107 Nice cedex 02
Dmitry Bulavin, MD, PhD, Professor
IRCAN, 06107 Nice Cedex 02 France
DB received his MD from the Medical Academy (St. Petersburg, Russia), where he also completed a PhD program in biochemistry and molecular biology. During a postdoc at the NIH, Dr. Bulavin identified a novel role for p38 MAP kinase in negative regulation of tumorigenesis , the direction that is now widely pursued in the cancer field. Subsequently, Dr.Bulavin made important discoveries in establishing the key role of a novel phosphatase Wip1 as a potent human oncogene, this finding catalyzed the development of novel anti-cancer drugs by several companies. His academic research is primarily in the field of cancer molecular biology, with partcular emphasis on the role of DNA damage and stress response signalling. After becoming fully independent, Dr.Bulavin continued interrogating the role of Wip1 phosphatase and p38 MAP kinase in cancer but also in other pathological conditions as well as during aging. Since 2013, Dr. Bulavin is a full professor at INSERM (France).
James W. Simpkins, Professor,
Director, Center for Basic & Translational Stroke Research
West Virginia University, USA,
Past President of International Society on Aging and Disease.
Dr. James W. Simpkins has served as Chairman of the Department of Pharmacodynamics, Chairman of the Department of Pharmaceutics, Associate Dean for Research and Graduate Studies and Director, Center for the Neurobiology of Aging at the University of Florida since 2004. Dr. Simpkins was appointed as the Frank Duckworth Professor of Drug Discovery at the University of Florida in 1996. He has more than 295 peer-reviewed publications, a dozen patents for his discoveries and has edited two texts on Alzheimer's disease therapy. He also served as the Director of the University of Florida Drug Discovery Group for Alzheimer's disease, which has sustained funding by the National Institute on Aging to support research in the pharmacotherapy for Alzheimer's disease. In 1999 he was appointed to the Medical and Scientific Advisory Council of the National Alzheimer's Association. In July of 2000, he became the Chair of the Department of Pharmacology and Neuroscience and Director, Institute for Aging and Alzheimer's Disease Research at the University of North Texas Health Science at Fort Worth. Dr. Dr. James W. Simpkins is currently the director Center for Basic & Translational Stroke Research, West Virginia University, USA.
Michael Forster, Ph.D., Chairman and Regents Professor,
University of North Texas Health Science Center (UNTHSC), USA
Past President of the International Society on Aging and Disease, and Past President of the American Aging Association
Dr. Forster is recognized internationally for research on the role of oxidative stress in age-associated brain dysfunction and in the anti-aging effects of caloric restriction. Dr. Forster is Director of the UNTHSC site for the National Institute on Drug Abuse- Addiction Treatment Discovery Program (ATDP), and has directed his program continuously with National Institute on Drug Abuse- Addiction Treatment Discovery Program (ATDP) for 20 years, evaluating and reporting on over 3,000 potential medications for the treatment of drug addition, using behavioral pharmacology methods of analysis. In addition, Dr. Forster developed and validated rodent models for assessment of age-related changes in brain function and established outstanding testing facilities appropriate for assessing the effects of long-term interventions.
Dr Forster served on the editorial board of Experimental Biology and Medicine, Mechanisms of Ageing and Development, and Journal of the American Aging Association, has been the recipient of numerous local and national awards for academic excellence, and has been awarded the title of Regents Professor. He is currently immediate past President of The American Aging Association, an international organization dedicated to basic research in biogerontology.
Bjoern Schumacher, Ph.D., Professor
Head of Research Area C – Principal Investigator, Chair for Genome Stability in Ageing and Disease
Prof. Dr. Björn Schumacher’s research group uses the nematode worm Caenorhabditis elegans to understand the causal role of DNA damage in aging and disease. With increasing age, damage to the genome accumulates and leads to the degeneration of cells and tissues. DNA damage thus plays a causal role in aging-associated diseases. The risk of cancer also increases with age because erroneously repaired DNA leads to mutations that can trigger cancer. Schumacher’s team has identified mechanisms that antagonize the detrimental consequences of DNA damage by maintaining tissue integrity and maximizing lifespan, even when the DNA damage cannot be repaired. The Schumacher group has also shown that DNA damage in individual cells impacts the entire organism. The systemic DNA damage responses are mediated by the immune system and increase the general stress resistance of the tissues throughout the body. These findings are particularly important for understanding progeria, disorders that result in premature aging in childhood. Premature aging is caused by congenital dysfunction of the DNA repair processes. Understanding the mechanisms by which organisms respond to accumulating DNA damage with age is pivotal for developing novel therapies to prevent aging-associated diseases and contribute to optimizing cancer treatment.
Prof. Schumacher’s group has shown that organisms respond to DNA damage by activating genetic mechanisms that prolong life. The focus is on understanding how this response to DNA damage is regulated so that the organism can maximize its survival even if the DNA cannot be repaired. Schumacher’s team has already identified mechanistic links between the ge-netic aging process and the stochastic accumulation of DNA damage. Schumacher and his team have revealed a previously unknown systemic immune response in C. elegans. Their key finding is that an immune response activated in individual cells in response to DNA damage can be transmitted throughout the entire body to promote survival of the organism in the face of further stress. Prof. Bjorn Schumacher has been awarded the Innovation Prize from the State of North Rhine-Westphalia, holds the ERC starting grant and coordinates the European training network “CodeAge” on chronic DNA damage responses in aging.
Robert Chunhua Zhao M.D., Ph.D
Regional Editor (Asia-Pacific) , Stem Cells and Development
Cheung Kong Scholar of Stem Cell Biology
Director, The Center of Excellence in Tissue Engineering
Director, Institute of Basic Medical Sciences and School of Basic Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College
Director, Beijing Key Laboratory of New Drug Development and Clinical Trial of Stem Cell Therapy
Adjunct Professor, Department of Anatomy and Developmental Biology, Monash University
Chief Scientist of 973 Program、863 Program、National Science and Technology Major Project、National key scientific research project
Professor Robert C.H. Zhao is Cheung Kong Professor of Stem Cell Biology and Director of Center of Excellence on Tissue Engineering at Chinese Academy Medical Sciences & Peking Union Medical College. His research is directed at studying the fundamental properties of stem cells and translating their unique biological properties into clinical application. Dr. Zhao had a six-year working experience at University of Minnesota. In 1998, he was promoted Assistant Professor of Division of Hematology Oncology & Transplantation and Stem Cell Institute at University of Minnesota. In the year 2000, Dr. Zhao came back to China and served as Executive Director of State Key Laboratory of Experimental Hematology. He established the National Center for stem cell research, as an integrated base to conduct basic stem cell research and facilitate the transition from bench to bedside. He also serves as a Regional Editor of Stem Cells and Development.
Over the past decade, Dr. Zhao has published 352 papers in international and domestic journals (including 162 SCI cited papers). As a leading scientist in adult stem cell research, he launched collaboration with National Institute for the Control of Pharmaceutical and Biological Products (NICPBP) and drafted the first standard, stringent and high-quality procedure for mesenchymal stem cell culture and qualification, and also set up the SOP for large-scale stem cell production. In 2004, his group won the first official approval of a stem cell product-“mesenchymal stem cell” from SFDA as to start clinical trials in China. In recognition of his achievements in adult stem cell research, National Key Scientific Program of China (973), “863 Projects” of Ministry of Science and Technology, Cheung Kong Scholars Programme, China National Funds for Distinguished Young Scientists and National Natural Science Foundation etc. were all supportive of his work. Dr. Zhao was awarded the 1st Prize of Technological Invention from Ministry of Education in 2007 and the 2nd Prize of National Technological Invention in 2009.
Ashok K. Shetty, Ph.D., Professor
Director of Neurosciences, Institute for Regenerative Medicine
Texas A & M Health Science Center College of Medicine, USA
Co-Editor-in-Chief of Aging and Disease
Associate Editor of Frontiers in Epilepsy
Ashok K. Shetty is Director of Neurosciences at the Institute for Regenerative Medicine located in Temple, Texas, and Professor in the Department of Molecular and Cellular Medicine. Dr. Shetty is also Research Career Scientist at the Olin E. Teague Veterans’ Affairs Medical Center, Central Texas Veterans Health Care System in Temple.
From 2004 to 2008, Dr. Shetty served as a Charter Member of the National Institutes of Health Study Section CNNT (Brain Disorders and Clinical Neuroscience ZRG1). He has also served as an ad hoc member of over 25 other NIH study sections, and as a reviewer of grant applications for over 12 international funding agencies from Germany, France, England, Israel, India and Singapore. Presently, Dr. Shetty is a charter member of the NIH Study Section, Developmental Brain Disorders (Brain Disorders and Clinical Neuroscience IRG). Dr. Shetty also serves as an Editorial Board Member of many international journals, which include Stem Cells, Aging Cell, Stem Cells International, Current Aging Science, Frontiers in Neurogenesis, Frontiers in Aging Neuroscience, and Stem Cells and Cloning. Dr. Shetty is among the top 1% of scientists worldwide in the field of Neuroscience and Behavior, in terms of citations received for published articles over 10-year period.